Segmented Polypeptides for ABCA1-Mediated Cholesterol Efflux
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for treating cardiovascular disease, particularly atherosclerosis, face challenges in effectively manipulating the reverse cholesterol transport pathway due to limitations with full-length Apo A-I proteins, such as production complexity and immunogenic responses, necessitating alternative compositions and methods for stabilizing and regressing atherosclerotic plaques.
Innovation Solution
Development of a family of non-naturally occurring polypeptides with high-affinity binding to ABCA1, stimulating cholesterol efflux and stabilizing the ABCA1 transporter, which can be used alone or in combination with other pharmacological agents to treat cardiovascular disease, reduce atherosclerosis, and promote reverse cholesterol transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If full-length Apo A-I proteins are used to mediate reverse cholesterol transport, then cholesterol efflux activity is achieved, but production complexity and immunogenic responses increase
Solution Approach 1:
The patent segments the full-length Apo A-I protein into smaller functional domains, specifically identifying and utilizing the N-terminal domain (residues 1-107) as a sufficient functional unit for cholesterol efflux activity. This segmentation reduces production complexity while maintaining therapeutic efficacy, as the truncated polypeptide retains the essential ABCA1 binding capability without requiring synthesis of the complete 243-amino acid protein.
Solution Approach 2:
The patent extracts the essential functional domain from the full-length Apo A-I protein, isolating the N-terminal region that contains the critical ABCA1 binding interface. By taking out only the necessary segment (residues 1-107 or shorter variants), the invention eliminates unnecessary portions of the protein that contribute to production difficulty and immunogenicity while preserving the core cholesterol efflux function.
2Reliability
If full-length Apo A-I proteins are used to mediate reverse cholesterol transport, then cholesterol efflux activity is achieved, but immunogenic responses increase
Solution Approach 1:
By segmenting Apo A-I into smaller polypeptide fragments (particularly the N-terminal domain), the patent reduces the molecular size and structural complexity that trigger immune responses. The truncated polypeptides (e.g., residues 1-107 or shorter) present fewer epitopes to the immune system while maintaining ABCA1 binding activity, thereby reducing immunogenicity.
Solution Approach 2:
The patent extracts only the essential N-terminal functional domain from full-length Apo A-I, removing the C-terminal region that may contain immunodominant epitopes. This extraction strategy retains the ABCA1 interaction capability while eliminating portions of the protein that could provoke stronger immune responses.
3Reliability
If statins are used to lower plasma LDL concentrations, then approximately one-third of CVD events are prevented, but two-thirds of events remain unaddressed
Solution Approach 1:
The patent introduces synthetic polypeptide mediators that specifically target and activate ABCA1 transporters in macrophages, creating a direct pathway for cholesterol efflux independent of LDL lowering. This intermediary mechanism bypasses the limitations of statin therapy by directly promoting reverse cholesterol transport through ABCA1-mediated efflux to ApoA-I or synthetic analogs, addressing the unmet need in two-thirds of CVD patients.
Solution Approach 2:
The patent changes the therapeutic parameter from LDL concentration reduction (statin mechanism) to direct ABCA1 activation and cholesterol efflux promotion. By shifting the mechanism of action to enhance HDL-mediated reverse cholesterol transport and macrophage cholesterol removal, the treatment addresses a different pathological pathway that complements statin therapy and covers the unmet medical need.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides demonstrate potent and selective activity for ABCA1, effectively stimulating cholesterol efflux, reducing atherosclerosis severity, and preventing its development in animal models, offering a therapeutic approach to manage cardiovascular disease and dyslipidemia.
Implementation Method 1
Development of a family of non-naturally occurring polypeptides with high-affinity binding to ABCA1, stimulating cholesterol efflux
Data Source
AI summary
The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABAC1 that parallels that of full-length apolipoproteins. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.